CTXR

Citius Pharmaceuticals, Inc.

Sağlık

COMPLIANT — All screening ratios are below the thresholds; the company is compliant with halal investment criteria.

$0.53

Price (1 Year)

$1.44 $0.4

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %9.7 / %30
Non-compliant assets / Total market cap %0 / %30
Non-compliant revenue / Total income %2.9 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma.

Website

Analysis (Turkish): CTXR Hissesi Caiz mi, Helal mi? Citius Pharmaceuticals, Inc. Katılım Analizi